VKTX logo

Viking Therapeutics Inc (VKTX)

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients wit...

NASDAQHealthcareBiotechnologyUSA

Company Profile

Stock Code
VKTX
ISIN Code
US92686J1060
Currency
US Dollar (USD)
IPO Date
2015-04-29

Contact Information

Company Address
9920 Pacific Heights Boulevard, San Diego, CA, United States, 92121
Contact Phone
858 704 4660
Company Website
https://www.vikingtherapeutics.com
Fiscal Year End
December

Financial Highlights

Market Capitalization
$999,999.99
Gross Profit (TTM)
$0
Return on Assets (TTM)
-51.86%
Revenue (TTM)
$0